

# 36<sup>th</sup> World Cancer Conference & 3<sup>rd</sup> Edition of International Conference on **Colorectal Cancer**

October 11-13, 2018 Zurich, Switzerland

## **Immunoscore® colon clinical validation and clinical utility in stage II and stage III colon cancer patients**

**Karim Belaloui**  
HalioDx, France

Immunoscore® colon is an *in vitro* diagnostic test predicting the risk of relapse in early-stage colon cancer patients, by measuring the host immune response at the tumor site. It is a risk-assessment tool that provides independent and superior prognostic value than the usual tumor risk parameters and is intended to be used as an adjunct to the TNM classification. Risk assessment is particularly important in order to decide when to propose an adjuvant treatment to an individual patient. Generally, adjuvant treatment is recommended for stage III and 'high-risk' stage II patients. There are still unmet medical needs to better improve the estimation of risk-of-recurrence of patients with colon cancer, especially to identify patients in Stage II who need treatment and identify patients in Stage III who would be harmed by reducing treatment duration based primarily on tumor and node staging. A number of poor prognostic factors have been identified but none has been shown to improve the selection of patients. Extensive literature has documented the host immune response against cancer and demonstrated the prognostic impact of the *in situ* immune cell infiltrate in tumors. Development and validation of the analytical and diagnostic performance of the Immunoscore® Colon assay will be presented and discussed. The clinical utility of the test will be highlighted by subgroups analysis (MSI & MSS tumors among Stage II patients, T1-T3 N1 versus T4 and/or N2 tumors among Stage III), supporting the implementation of Immunoscore® Colon as a new component for the classification of cancer, TNM-I (Immune).

### **Recent Publications**

1. Pagès F, et al. (2018) International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet Journal 391(10135):2128-2139.

### **Biography**

Dr Karim Belaloui is Medical Director at HalioDx which develop Immunoscore® which is a risk assessment tool validated by an International Consortium study led by the SITC. Karim Belaloui is a Medical Doctor with 20 years' experience in immunology and oncology area successively in clinical practice, academic research and pharmaceutical industry, with large Research & Development background and Medical expertise in Chemotherapy agents, Tyrosine kinase inhibitors, Immunotherapy and immune-oncology diagnostic tests.

karim.belaloui@haliodx.com

### **Notes:**